Still Far to Go With Characterisation of Molecular and Genetic Features of Diffuse Large B-Cell Lymphoma in People Living With HIV: A Scoping Review

Maudy C P Manyau; Blessing Zambuko; Moses Chatambudza; Danai T Zhou; Justen Manasa

doi:10.3389/or.2024.1375291

Still Far to Go With Characterisation of Molecular and Genetic Features of Diffuse Large B-Cell Lymphoma in People Living With HIV: A Scoping Review

Oncol Rev. 2024 Apr 19:18:1375291. doi: 10.3389/or.2024.1375291. eCollection 2024.

Authors

Maudy C P Manyau^{1

2}, Blessing Zambuko³, Moses Chatambudza¹, Danai T Zhou^{1

2}, Justen Manasa^{1

2}

Affiliations

¹ Laboratory Diagnostic and Investigative Sciences, University of Zimbabwe, Harare, Zimbabwe.
² Biomedical Research and Training Institute, Harare, Zimbabwe.
³ Lancet Laboratories, Pathology, Harare, Zimbabwe.

Abstract

Diffuse large B-cell lymphoma (DLBCL) accounts for half of non-Hodgkin lymphoma cases in people living with human immunodeficiency syndrome (PLWH). The interplay of viremia, immune dysregulation and co-infection with oncogenic viruses play a role in pathogenesis of DLBCL in PLWH (HIV-DLBCL). This scoping review aimed to describe the molecular landscape of HIV-DLBCL, investigate the impact of biomarker on clinical outcomes and describe technologies used to characterise HIV-DLBCL. Thirty-two papers published between 2001 and 2023 were included in this review. Samples of HIV-DLBCL were relatively small (16-110). Cohort effects influenced frequencies of molecular characteristics hence their impact on survival was not clear. Molecular features were distinct from HIV-unrelated DLBCL. The most frequently assessed characteristic was cell of origin (81.3% of studies). Somatic mutations were the least researched (6.3% of studies). Overall, biomarker identification in HIV-DLBCL requires broader richer data from larger or pooled samples using more powerful techniques such as next-generation sequencing.

Keywords: BCL6; CD10; CD138; HIV/AIDS; MUM1; cyclin H; molecular pathology histogenesis; non-Hodgkin lymphoma.

Publication types

Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Research reported in this publication was supported by the Fogarty International Center of the National Institutes of Health under Award Number D43 TW011326. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.